United Kingdom-Runcorn: NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga)

Type of document: Contract Notice
Country: United Kingdom
Publication Ref: (2021/S 000-013184/EN)
Nature of contract: Supply contract
Procedure: Negotiated without a call for competition
Type of bid required: Not applicable

Voluntary ex ante transparency notice
Supplies

Section I: Contracting authority
I.1) Name and addresses
Official name: The NHS Commissioning Board (operating under the name of NHS England)
Postal address: 2nd Floor, Rutland House
Town: Runcorn
Postal code: WA7 2ES
Country: United Kingdom
Contact Person: Philip Grieve
Email: philip.grieve@nhs.net
Internet address(es):
Main address: www.england.nhs.uk

I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local sub-divisions
I.5) Main activity
Health

Section II: Object
II.1) Scope of the procurement
II.1.1) Title: NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga)

Reference number: CM/PHS/21/5642
II.1.2) Main CPV code: 33651520
II.1.3) Type of contract Supplies
II.1.4) Short Description:
NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga). The framework will commence on 1 June 2021 for a period of 7 months, with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 6 months. Total maximum framework agreement including extension options will be no more than 13 months.
II.1.6) Information about lots
The contract is divided into lots: no
II.1.7) Total value of the procurement(excluding VAT)
Value:17595000
Currency:GBP
II.2) Description
II.2.2)Additional CPV code(s)
Main CPV code: 33651520

II.2.3) Place of performance
Nuts code: Main site or place of performance:ITT lists Purchasing Points. Framework intended for use by the NHS in England, Scotland Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above

II.2.4) Description of the procurement
NHS Framework Agreement for the Supply of Human Normal Immunoglobulin (Panzyga). Period of framework agreement: 1 June 2021 to 31 December 2021 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 6 months. Total maximum framework agreement including extension options will be no more than 13 months.

II.2.5) Award criteria
II.2.11) Information about options
Options:yes
Description of options:
Period of framework agreement: 1 June 2021 to 31 December 2021 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 6 months. Total maximum framework agreement including extension options will be no more than 13 months.

II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Negotiated procedure without prior publication(in accordance with Article 32 of Directive 2014/24/EU)
IV.1.3) Information about framework agreement
The procurement involves the establishment of a framework agreement
IV.1.8) Information about the Government Procurement Agreement(GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2) Administrative information

Section V: Award of contract/concession
V.2) Award of contract/concession
V.2.1) Date of conclusion of the contract/concession award decision:2021-06-10
V.2.2) Information about tenders
V.2.3) Name and address of the contractor
Official name: Octapharma Limited
Town: Manchester
Country: United Kingdom
Nuts code:
The contractor is an SME: no

V.2.4) Information on value of the contract/lot/concession(excluding VAT)
for framework agreements – total maximum value for this lot
for contracts based on framework agreements, if required – value of contract(s) for this lot not included in
previous contract award notices

Section VI: Complementary informationVI.4) Procedures for review
VI.4.1) Review body
Official name: The High Court
Town: London
Country: United Kingdom

VI.5) Date of dispatch of this notice:
2021-06-11

Justification for the award of the contract without prior publication of a call for
competition in the Official Journal of the European Union
1.Justification for the choice of the negotiated procedure without prior publication of a call for competition in accordance with Article
32 of Directive 2014/24/EU
Extreme urgency brought about by events unforeseeable for the contracting authority and in accordance with the strict conditions stated in the
directive

3.Explanation
Please explain in a clear and comprehensive manner why the award of the contract without prior publication in the Official Journal of the European Union
is lawful, by stating the relevant facts and, as appropriate, the conclusions of law in accordance with the directive:
An urgent need to secure additional supply of Human Normal Immunoglobulin as a result of the ongoing global supply shortages